Construction of a rabbit model with vinorelbine administration via peripherally inserted central catheter and dynamic monitoring of changes in phlebitis and thrombosis

Huang,Liquan; Chen,Guiyuan; Hu,Qinghua; Hu,Bo; Zhu,Louying; Fang,Luyan

doi:10.3892/etm.2022.11135

Construction of a rabbit model with vinorelbine administration via peripherally inserted central catheter and dynamic monitoring of changes in phlebitis and thrombosis

Authors:
- Liquan Huang
- Guiyuan Chen
- Qinghua Hu
- Bo Hu
- Louying Zhu
- Luyan Fang
View Affiliations

Affiliations: Nursing Faculty, School of Medicine, Jinhua Polytechnic, Jinhua, Zhejiang 321007, P.R. China, Department of Orthopedics, Jinhua Hospital of Traditional Chinese Medicine, Jinhua, Zhejiang 321000, P.R. China, Department of Obstetrics and Gynecology, Jinhua People's Hospital, Jinhua, Zhejiang 321000, P.R. China, Jinhua Center of Laboratory Animals, Jinhua Food and Drug Inspection and Testing Institute, Jinhua, Zhejiang 321000, P.R. China
Published online on: January 11, 2022 https://doi.org/10.3892/etm.2022.11135
Article Number: 212
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peripherally inserted central catheters (PICCs) are used for the administration of chemotherapy drugs, including vinorelbine. The present study aimed to construct a rabbit model with vinorelbine administration via PICC, and to dynamically monitor the formation of phlebitis and thrombosis. PICC was inserted into 48 rabbits following specific clinical procedures. The rabbits were randomly divided (n=6 per group) into the following eight groups: i) Control (PICC in place for 1 day); ii) 2nd day of PICC placement (received the first cycle of vinorelbine administration); iii) 3rd day of PICC placement; iv) 7th day of PICC placement; v) 14th day of PICC placement; vi) 21st day of PICC placement; vii) 23rd day of PICC placement (received the second cycle of vinorelbine administration); and viii) 24th day of PICC placement. Hematoxylin and eosin staining was performed on catheter, ear vein and anterior vena specimens. Prothrombin time was measured using an automatic coagulation analyzer, followed by routine blood tests. Serum levels of inflammation‑ and thrombosis‑related factors, including C‑reactive protein, D‑dimer, interleukin‑2, interleukin‑6, P‑selectin and E‑selectin, were measured using ELISAs. X‑ray examination confirmed that the rabbit model with vinorelbine administration via PICC was successfully constructed. On the 1st and 23rd day of PICC placement, thrombosis was observed in the catheter. Furthermore, on the 1st day of PICC placement, thrombosis was clearly observed in the ear vein and anterior vena samples. After vinorelbine administration, phlebitis occurred in the ear vein and anterior vena cava samples. With increasing time after vinorelbine administration via PICC, thrombosis and phlebitis were notably ameliorated. Moreover, on the day of vinorelbine administration, prothrombin time was significantly decreased and the serum levels of inflammation‑ and thrombosis‑related factors were significantly increased compared with previous days. Collectively, the present study observed the formation and specific evolution of phlebitis and venous thrombosis after vinorelbine administration, providing a reference for the early prediction, timely prevention and treatment of PICC‑related chemotherapy complications.

View Figures

View References

1	Keren R, Shah SS, Srivastava R, Rangel S, Bendel-Stenzel M, Harik N, Hartley J, Lopez M, Seguias L, Tieder J, et al: Comparative effectiveness of intravenous vs oral antibiotics for postdischarge treatment of acute osteomyelitis in children. JAMA Pediatr. 169:120–128. 2015.PubMed/NCBI View Article : Google Scholar
2	Campagna S, Gonella S, Berchialla P, Morano G, Rigo C, Zerla PA, Fuzzi R, Corona G, Storto S, Dimonte V and Mussa B: Can peripherally inserted central catheters be safely placed in patients with cancer receiving chemotherapy? A retrospective study of almost 400,000 catheter-days. Oncologist. 24:e953–e959. 2019.PubMed/NCBI View Article : Google Scholar
3	Taxbro K, Hammarskjöld F, Thelin B, Lewin F, Hagman H, Hanberger H and Berg S: Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: An open-label, randomised, two-centre trial. Br J Anaesth. 122:734–741. 2019.PubMed/NCBI View Article : Google Scholar
4	Yu D, Zhang K, Huang L, Zhao B, Zhang X, Guo X, Li M, Gu Z, Fu G, Hu M, et al: Detection of peripherally inserted central catheter (PICC) in chest X-ray images: A multi-task deep learning model. Comput Methods Programs Biomed. 197(105674)2020.PubMed/NCBI View Article : Google Scholar
5	Jumani K, Advani S, Reich NG, Gosey L and Milstone AM: Risk factors for peripherally inserted central venous catheter complications in children. JAMA Pediatr. 167:429–435. 2013.PubMed/NCBI View Article : Google Scholar
6	Robinson A, Souied O, Bota AB, Levasseur N, Stober C, Hilton J, Kamel D, Hutton B, Vandermeer L, Mazzarello S, et al: Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: A systematic review. Breast Cancer Res Treat. 171:607–620. 2018.PubMed/NCBI View Article : Google Scholar
7	Fallouh N, McGuirk HM, Flanders SA and Chopra V: Peripherally inserted central catheter-associated deep vein thrombosis: A narrative review. Am J Med. 128:722–738. 2015.PubMed/NCBI View Article : Google Scholar
8	Lv S, Liu Y, Wei G, Shi X, Chen S and Zhang X: The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients. Medicine (Baltimore). 98(e17894)2019.PubMed/NCBI View Article : Google Scholar
9	Pu YL, Li ZS, Zhi XX, Shi YA, Meng AF, Cheng F, Ali A, Li C, Fang H and Wang C: Complications and costs of peripherally inserted central venous catheters compared with implantable port catheters for cancer patients: A meta-analysis. Cancer Nurs. 43:455–467. 2020.PubMed/NCBI View Article : Google Scholar
10	Perri F, Lazzari G, Scarpati GD and Silvano G: Oral vinorelbine: A feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer. Onco Targets Ther. 9:2359–2364. 2016.PubMed/NCBI View Article : Google Scholar
11	Diaby V, Tawk R, Sanogo V, Xiao H and Montero AJ: A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat. 151:27–40. 2015.PubMed/NCBI View Article : Google Scholar
12	Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, et al: Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial. Lancet Oncol. 17:357–366. 2016.PubMed/NCBI View Article : Google Scholar
13	Mondal A, Gandhi A, Fimognari C, Atanasov AG and Bishayee A: Alkaloids for cancer prevention and therapy: Current progress and future perspectives. Eur J Pharmacol. 858(172472)2019.PubMed/NCBI View Article : Google Scholar
14	Jonna S, Reuss JE, Kim C and Liu SV: Oral chemotherapy for treatment of lung cancer. Front Oncol. 10(793)2020.PubMed/NCBI View Article : Google Scholar
15	Rossi D, Catalano V, Alessandroni P, Fedeli A, Fedeli SL, Giordani P, Baldelli AM, Casadei V, Ceccolini M, Ugolini M, et al: A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer. Clin Lung Cancer. 8:382–385. 2007.PubMed/NCBI View Article : Google Scholar
16	Markert JE, Jasien JV, Turner DC, Huisingh C, Girkin CA and Downs JC: IOP, IOP transient impulse, ocular perfusion pressure, and mean arterial pressure relationships in nonhuman primates instrumented with telemetry. Invest Ophthalmol Vis Sci. 59:4496–4505. 2018.PubMed/NCBI View Article : Google Scholar
17	Ohwada K: Body surface area of the golden Syrian hamster. Jikken Dobutsu. 41:221–224. 1992.PubMed/NCBI View Article : Google Scholar
18	Oragano CA, Patton D and Moore Z: Phlebitis in intravenous amiodarone administration: Incidence and contributing factors. Crit Care Nurse. 39:e1–e12. 2019.PubMed/NCBI View Article : Google Scholar
19	Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F and Barton MB: Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: A population-based study. Lancet Oncol. 20:769–780. 2019.PubMed/NCBI View Article : Google Scholar
20	Bertoglio S, Cafiero F, Meszaros P, Varaldo E, Blondeaux E, Molinelli C and Minuto M: PICC-PORT totally implantable vascular access device in breast cancer patients undergoing chemotherapy. J Vasc Access. 21:460–466. 2020.PubMed/NCBI View Article : Google Scholar
21	Bertoglio S, Faccini B, Lalli L, Cafiero F and Bruzzi P: Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures. J Surg Oncol. 113:708–714. 2016.PubMed/NCBI View Article : Google Scholar
22	Qi F, Cheng H, Yuan X and Zhang L: Comparison of PICC and TIVAP in chemotherapy for patients with thyroid cancer. Oncol Lett. 20:1657–1662. 2020.PubMed/NCBI View Article : Google Scholar
23	Wang G, Li Y, Wu C, Guo L, Hao L, Liao H, Xiao X, Liu S and Luo L: The clinical features and related factors of PICC-related upper extremity asymptomatic venous thrombosis in cancer patients: A prospective study. Medicine (Baltimore). 99(e19409)2020.PubMed/NCBI View Article : Google Scholar
24	Picardi M, Della Pepa R, Cerchione C, Pugliese N, Mortaruolo C, Trastulli F, Giordano C, Grimaldi F, Zacheo I, Raimondo M, et al: A frontline approach with peripherally inserted versus centrally inserted central venous catheters for remission induction chemotherapy phase of acute myeloid leukemia: A randomized comparison. Clin Lymphoma Myeloma Leuk. 19:e184–e194. 2019.PubMed/NCBI View Article : Google Scholar
25	Ng VL: Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med. 29:253–263. 2009.PubMed/NCBI View Article : Google Scholar
26	Tripodi A: Prothrombin time international normalized ratio monitoring by self-testing. Curr Opin Hematol. 11:141–145. 2004.PubMed/NCBI View Article : Google Scholar
27	Yang DT, Robetorye RS and Rodgers GM: Home prothrombin time monitoring: A literature analysis. Am J Hematol. 77:177–186. 2004.PubMed/NCBI View Article : Google Scholar
28	Naghadeh HT, Maghsudloo M and Tabatabaei MR: Coagulation factors V, VIII, and X, prothrombin time and activated partial thromboplastin time test results in thawed plasma stored at 1-6˚C for 5 days. Blood Transfus. 9:95–98. 2011.PubMed/NCBI View Article : Google Scholar
29	Onundarson PT, Francis CW, Indridason OS, Arnar DO, Bjornsson ES, Magnusson MK, Juliusson SJ, Jensdottir HM, Vidarsson B, Gunnarsson PS, et al: Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: A single centre, double-blind, randomised, non-inferiority trial. Lancet Haematol. 2:e231–240. 2015.PubMed/NCBI View Article : Google Scholar
30	Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, Bertolaso L, Menon D, Crepaldi G, Bononi A, et al: Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: Correlations with pharmacokinetics and MDR1 polymorphisms. Cancer Chemother Pharmacol. 83:493–500. 2019.PubMed/NCBI View Article : Google Scholar
31	Yao Z, Zhang Y and Wu H: Regulation of C-reactive protein conformation in inflammation. Inflamm Res. 68:815–823. 2019.PubMed/NCBI View Article : Google Scholar
32	Pathak A and Agrawal A: Evolution of C-reactive protein. Front Immunol. 10(943)2019.PubMed/NCBI View Article : Google Scholar
33	Setiadi H, Yago T, Liu Z and McEver RP: Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis. Blood Adv. 3:168–183. 2019.PubMed/NCBI View Article : Google Scholar
34	Wei Y, Chen X, Shen H, Wu W, Cao G, Chen W, Wang Y, Shen H, Yu S and Zhang J: P-selectin level at first and third day after portal hypertensive splenectomy for early prediction of portal vein thrombosis in patients with cirrhosis. Clin Appl Thromb Hemost. 24 (9_Suppl):76S–83S. 2018.PubMed/NCBI View Article : Google Scholar
35	Riva N, Camporese G, Iotti M, Bucherini E, Righini M, Kamphuisen PW, Verhamme P, Douketis JD, Tonello C, Prandoni P, et al: Age-adjusted D-dimer to rule out deep vein thrombosis: Findings from the PALLADIO algorithm. J Thromb Haemost. 16:271–278. 2018.PubMed/NCBI View Article : Google Scholar
36	Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ, et al: Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 349:1227–1235. 2003.PubMed/NCBI View Article : Google Scholar
37	Orlandi P, Banchi M, Alì G, Desidero TD, Fini E, Fontanini G and Bocci G: Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma. J Chemother. 33:198–202. 2021.PubMed/NCBI View Article : Google Scholar